Trial · NCT07343206
Registered outcomes11
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 11 of 11
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | 28-day survival | From enrollment to 28 days after enrollment | Survival at 28-day after enrollment. Telephone follow-up for patients who are discharged before 28 days. |
| Secondary | Number of participants with shock control achieved | From enrollment to 6 hours after enrollment | Shock control defined as mean arterial pressure greater than 65 mmHg combined with urine output greater than 0.5 milliliters per kilogram per hour OR lactate clearance greater than 10 percent within 6 hours |
| Secondary | Duration of intensive care unit stay | From enrollment to hospital discharge or 90 days (whichever comes first) | Days of intensive care unit stay |
| Secondary | Duration of hospital stay | From enrollment to hospital discharge or 90 days (whichever comes first) | Days of hospital stay |
| Secondary | Duration of mechanical ventilation | From enrollment to hospital discharge or 90 days (whichever comes first) | Days on mechanical ventilation, including endotracheal tube and tracheostomy |
| Secondary | Duration of renal replacement therapy | From enrollment to hospital discharge or 90 days (whichever comes first) | Days requiring renal replacement therapy, including continuous renal replacement therapy, intermittent hemodialysis, and peritoneal dialysis, that is newly initiated during this admission. Maintaining chronic hemodialysis is excluded. |
| Secondary | Duration of vasopressor therapy | From enrollment to hospital discharge or 90 days (whichever comes first) | Days requiring vasopressor therapy |
| Secondary | Time to Achievement of Early Goal-Directed Therapy Targets | From study drug initiation until achievement of all EGDT targets or up to 6 hours | Time in hours to achieve ALL EGDT targets: MAP ≥65 mmHg, urine output ≥0.5 mL/kg/hr, lactate clearance ≥10%, and ScvO₂ ≥70% (when measured) |
| Secondary | Cumulative Fluid Volume Administered | Multiple assessments at: - Before randomization (baseline) - 1 hour after study drug initiation - 6 hours after study drug initiation - 24 hours (Day 1) 48 hours (Day 2) 72 hours (Day 3) after study drug initiation | Total volume in milliliters of intravenous crystalloid and colloid fluids administered during first 24 hours and first 72 hours Time Frame: At 1 hour, 6 hours, 24 hours (Day 1), 48 hours (Day 2), and 72 hours (Day 3) after treatment initiation |
| Secondary | Incidence of Pulmonary Edema | From diagnosis until hospital discharge 90 days or death | New-onset cardiogenic pulmonary edema or non-cardiogenic pulmonary edema |
| Secondary | Treatment-Related Adverse Events Including Cardiac Arrhythmias | From study drug initiation until hospital discharge or death, assessed 90 days | Composite outcome including new-onset arrhythmias (AF, AFL, SVT, VT, VF, AV block, bradycardia), limb/mesenteric ischemia, skin necrosis, and severe hypertension |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT07343206/registered